Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options - A mini-review

Gerontology

Volumn 60, Issue 4, 2014, Pages 294-305

  Ali, Sumbul ^a   Garcia, Jose M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Anorexia; Cachexia; Ghrelin; Inflammation; Sarcopenia; Testosterone

Indexed keywords

ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPROMORELIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOBOSARM; GHRELIN; GROWTH HORMONE; OMEGA 3 FATTY ACID; OXANDROLONE; PLACEBO; PROTEIN INHIBITOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; HUMAN GROWTH HORMONE; MUSCLE PROTEIN; PROTEIN INTAKE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MELANOCORTIN RECEPTOR; MYOSTATIN; SOMATOMEDIN C;

AGING; ARTHRALGIA; CACHEXIA; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EDEMA; EXERCISE; FLUID RETENTION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; MUSCLE FUNCTION; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SARCOPENIA; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION; WASTING SYNDROME; ADMINISTRATION AND DOSAGE; AGED; KINESIOTHERAPY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN INTAKE; SKELETAL MUSCLE; AEROBIC EXERCISE; DIET THERAPY; NONHUMAN; RESISTANCE TRAINING;

AGED; AGING; ANDROGENS; APPETITE STIMULANTS; CACHEXIA; DIETARY PROTEINS; EXERCISE THERAPY; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; RECEPTORS, ANDROGEN; SARCOPENIA;

EID: 84903538743     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000356760     Document Type: Review

References (55)

1. US Census Bureau: Table 2. Projections of the population by selected age groups and sex for the United States: 2010 to 2050 (NP2008-T2); in Population Division, US Census Bureau. Washington, US Census Bureau, 2008.
2. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014-1019.
3. Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008; 23: 160-170.
4. Marzetti E, Carter CS, Wohlgemuth SE, Lees HA, Giovannini S, Anderson B, Quinn LS, Leeuwenburgh C: Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction. Mech Ageing Dev 2009; 130: 272-280.
5. Busquets S, Deans C, Figueras M, Moore-Carrasco R, Lopez-Soriano FJ, Fearon KC, Argiles JM: Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 2007; 26: 614-618.
6. Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, Chiarpotto EM, Cavallini G, Bonelli G, Baccino FM, Costelli P: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 2013; 182: 1367-1378.
7. Kang C, Chung E, Diffee G, Ji LL: Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1β. Exp Gerontol 2013; 48: 1343-1350.
8. Padrao AI, Oliveira P, Vitorino R, Colaco B, Pires MJ, Marquez M, Castellanos E, Neuparth MJ, Teixeira C, Costa C, Moreira-Goncalves D, Cabral S, Duarte JA, Santos LL, Amado F, Ferreira R: Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int J Biochem Cell Biol 2013; 45: 1399-1409.
9. Reed SA, Sandesara PB, Senf SM, Judge AR: Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 2012; 26: 987-1000.
10. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ: Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab 2007; 292:E151-E157.
11. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, de Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011; 12: 249-256.
12. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R: Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol 2000; 88: 1321-1326.
13. Lexell J: Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 1995; 50(spec No):11-16.
14. Janssen I, Heymsfield SB, Ross R: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896.
15. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R: The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 2004; 52: 80-85.
16. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC: Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) 'Cachexia-Anorexia in Chronic Wasting Diseases' and 'Nutrition in Geriatrics'. Clin Nutr 2010; 29: 154-159.
17. Drummond MJ, Miyazaki M, Dreyer HC, Pennings B, Dhanani S, Volpi E, Esser KA, Rasmussen BB: Expression of growth-related genes in young and older human skeletal muscle following an acute stimulation of protein synthesis. J Appl Physiol 2009; 106: 1403-1411.
18. Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, Jasuja R, Choi H, Gonzalez-Cadavid NF: The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58:M1103-M1110.
19. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS: The association of plasma IL-6 levels with functional disability in communitydwelling elderly. J Gerontol A Biol Sci Med Sci 1997; 52:M201-M208.
20. Brown WF: A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with ageing. J Neurol Neurosurg Psychiatry 1972; 35: 845-852.
21. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People: Sarcopenia: European consensus on definition and diagnosis-report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
22. Yarasheski KE, Pak-Loduca J, Hasten DL, Obert KA, Brown MB, Sinacore DR: Resistance exercise training increases mixed muscle protein synthesis rate in frail women and men 76 yr old. Am J Physiol 1999; 277:E118-E125.
23. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ: High-intensity strength training in nonagenarians: effects on skeletal muscle. JAMA 1990; 263: 3029-3034.
24. Liu CJ, Latham NK: Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009; 3:CD002759.
25. Calvani R, Miccheli A, Landi F, Bossola M, Cesari M, Leeuwenburgh C, Sieber CC, Bernabei R, Marzetti E: Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging 2013; 2: 38-53.
26. Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K, Muscaritoli M, Ponikowski P, Posthauer ME, Rossi Fanelli F, Schambelan M, Schols AM, Schuster MW, Anker SD; Society for Sarcopenia, Cachexia, and Wasting Disease: Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010; 11: 391-396.
27. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J: Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339:b3692.
28. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ: Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410-413.
29. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
30. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC: Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, doubleblind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
31. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S: Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
32. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force Endocrine Society: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
33. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS: The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebocontrolled phase II trial. J Cachexia Sarcopenia Muscle 2011; 2: 153-161.
34. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P: Hormone replacement therapy and physical function in healthy older men: time to talk hormones? Endocr Rev 2012; 33: 314-377.
35. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-611.
36. White HK, Petrie CD, Landschulz W, Mac-Lean D, Taylor A, Lyles K, Wei JY, Hoffman AR, Salvatori R, Ettinger MP, Morey MC, Blackman MR, Merriam GR; Capromorelin Study Group: Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94: 1198-1206.
37. di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, Williamson JD, Marchionni N, Pahor M: Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 961-966.
38. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, di Bari M, Guralnik JM, Pahor M: Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359: 926-930.
39. Sumukadas D, Witham MD, Struthers AD, McMurdo ME: Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007; 177: 867-874.
40. Rolland Y, Onder G, Morley JE, Gillette-Guyonet S, Abellan van Kan G, Vellas B: Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med 2011; 27: 423-447.
41. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD: Cachexia: a new definition. Clin Nutr 2008; 27: 793-799.
42. Tan BH, Fearon KC: Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400-407.
43. Morley JE, Thomas DR, Wilson MM: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83: 735-743.
44. Little JP, Phillips SM: Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab 2009; 34: 817-828.
45. op den Kamp CM, Langen RC, Haegens A, Schols AM: Muscle atrophy in cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr Metab Care 2009; 12: 611-616.
46. Baldwin C, Spiro A, Ahern R, Emery PW: Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 371-385.
47. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S: Megestrol acetate for treatment of anorexiacachexia syndrome. Cochrane Database Syst Rev 2013; 3:CD004310.
48. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573.
49. Orr R, Fiatarone Singh M: The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004; 64: 725-750.
50. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS: Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013; 14: 335-345.
51. Garcia JM, Friend J, Allen S: Therapeutic potential of anamorelin, a novel oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129-137.
52. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M: Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012; 4:CD008664.
53. DeBoer MD: Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition 2010; 26: 146-151.
54. Tsuchida K: Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008; 11: 487-494.
55. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011; 11: 1663-1668.